Durvalumab (Imfinzi) + enfortumab vedotin-ejfv approved by the US FDA for muscle-invasive bladder cancer (MIBC)
News
Regulatory decisions and trial results, in the order we post them.
Papers
- Could implant choice significantly change breast reconstruction outcomes after postmastectomy radiotherapy?Breast
Could implant choice significantly change breast reconstruction outcomes after postmastectomy radiotherapy?
Breast. Trial result. November 15, 2026.
- Rare prostate cancer histologiesGenitourinary
Rare prostate cancer histologies: detection, characteristics and treatment
Genitourinary. Trial result. Nature Reviews Urology. October 19, 2026.
- 44 out of 134: that’s how often the world’s top prostate cancer experts agreed.Genitourinary
Management of Patients with High-risk Localised, Locally Advanced, and Biochemically Recurrent Prostate Cancer: Report from the 2026 Advanced Prostate Cancer Consensus Conference
Genitourinary. Trial result. European Urology. October 27, 2026.
- A 0.42 hazard ratio for death in extensive-stage small-cell lung cancer.Lung and thoracic
Tarlatamab–Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer
Lung and thoracic. Trial result. NEJM. October 30, 2026.
- Can dual checkpoint inhibition redefine the treatment landscape in MSI-H/dMMR metastatic colorectal cancer?Gastrointestinal
CheckMate 8HW final results: dual checkpoint inhibition in MSI-H/dMMR metastatic colorectal cancer
Gastrointestinal. Trial result. Annals of Oncology. November 2, 2026.
- Is the next generation of KRAS G12C inhibitors changing the treatment landscape in advanced NSCLC?Lung and thoracic
Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC
Lung and thoracic. Trial result. NEJM. November 3, 2026.
Regulatory decisions
- FDAApprovedTalazoparib + enzalutamideGenitourinary
FDA approves talazoparib plus enzalutamide in prostate cancer with HRR gene mutations
Genitourinary. FDA. October 26, 2026.
- FDAAccelerated approvalDostarlimabGastrointestinal
FDA NEWS | AZUR 1 Update in Rectal Cancer
Gastrointestinal. FDA. October 19, 2026.
- FDAApprovedAtezolizumab with fluoropyrimidine + oxaliplatinGastrointestinal
Atezolizumab approved with fluoropyrimidine + oxaliplatin for adjuvant Stage III dMMR Colon Cancer (adults & peds ≥2 yrs).
Gastrointestinal. FDA. October 12, 2026.
- FDAApprovedTucatinib + trastuzumab + pertuzumabBreast
FDA NEWS: HER2CLIMB-05 Update
Breast. FDA. October 7, 2026.
The week in oncology, in your inbox
The OncoAlert Newsletter goes to 10,000+ oncologists and cancer stakeholders: every week, and every day during the major congresses. Free, independent, GDPR-compliant and easy to leave.



